ABSTRACT NUMBER: ESOC2026OT112 THE EFFICACY AND SAFETY OF INTRAVENOUS THROMBOLYSIS IN ACUTE ISCHEMIC STROKE PATIENTS WITH RECENT INGESTION OF FACTOR XA INHIBITORS TRIAL (SIFT)
Kim Lund Schultz, Håkon Ihle-Hansen, Hege Ihle-Hansen, Agnethe Eltoft, Annette Fromm, Fredrik Ildstad, Erik Koldberg Amundsen, Vojtech Novotny, Celine Marie Løken Cunen, Guri Hagberg · 2026
Read ABSTRACT NUMBER: ESOC2026OT112 THE EFFICACY AND SAFETY OF INTRAVENOUS THROMBOLYSIS IN ACUTE ISCHEMIC STROKE PATIENTS WITH RECENT INGESTION OF FACTOR XA INHIBITORS TRIAL (SIFT) by Kim Lund Schultz, Håkon Ihle-Hansen, Hege Ihle-Hansen, Agnethe Eltoft, Annette Fromm, Fredrik Ildstad, Erik Koldberg Amundsen, Vojtech Novotny, Celine Marie Løken Cunen, Guri Hagberg (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13144918.txt.
Description
Kim Lund Schultz and co-authors describe a 2026 trial that tests a clot-busting drug in stroke patients who recently took a common blood thinner. The drug is a standard, effective stroke treatment when given within a few hours. Current rules bar it for patients who took the thinner within the last two days, over fears of bleeding.
Earlier observational work hints the drug may still be safe and helpful for this group. The trial, run at many centers, assigns patients by chance in a two-to-one split to the drug or to standard care. Assessors who judge outcomes do not know who got what. Results should settle whether the rule can be eased.
Catalog record
| CREATOR | Kim Lund Schultz, Håkon Ihle-Hansen, Hege Ihle-Hansen, Agnethe Eltoft, Annette Fromm, Fredrik Ildstad, Erik Koldberg Amundsen, Vojtech Novotny, Celine Marie Løken Cunen, Guri Hagberg |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |